Skip to content
Screener

Pacira BioSciences, Inc. PCRX Business Segments — Total Costs & Expenses

Similar metrics at other companies

Twist Bioscience Corporation logo
TWSTReportable Segment — Total Costs & Expenses
$156.58M+16.5%
Lumen Technologies logo
LUMNReportable Segment — Total Costs & Expenses
$2.3B-25.3%
BlueLinx Holdings logo
BXCReportable Segment — Total Costs & Expenses
$732.61M+3.7%
Elanco Animal Health Inc. logo
ELANReportable Segment — Total Costs & Expenses
$596M+5.5%
Tarsus Pharmaceuticals, Inc. logo
TARSReportable Segment — Total Costs & Expenses
$193.82M+55.2%
DoorDash logo
DASHReportable Segment — Total Costs & Expenses
$4.3B+37.7%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$997.34M-11.9%
Enterprise value$1.26B+6.9%
P/E194.1×
P/S1.4×-0.2×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%
Net margin0.7%
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CostsAndExpenses.

The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028871
Line itemThree Months Ended March 31, 20262025
Selling, general and administrative93,94486,776
Amortization of acquired intangible assets14,32214,322
Other operating (gains) expenses, net(2,277)6,187
Total operating expenses170,474166,933
Income from operations6,9021,990
Other income (expense):
Interest income1,9306,895
Interest expense(3,699)(4,580)

Item 1. FINANCIAL STATEMENTS (Unaudited)

FAQ

What is Pacira BioSciences, Inc.'s business segments — total costs & expenses?
Pacira BioSciences, Inc. (PCRX) reported business segments — total costs & expenses of $170.47M in Q1 2026.
How has Pacira BioSciences, Inc.'s business segments — total costs & expenses changed year-over-year?
Pacira BioSciences, Inc.'s business segments — total costs & expenses increased by 2.1% year-over-year, from $166.93M to $170.47M.
What is the long-term trend for Pacira BioSciences, Inc.'s business segments — total costs & expenses?
Over 2 years (2022 to 2025), Pacira BioSciences, Inc.'s business segments — total costs & expenses has grown at a 8.0% compound annual growth rate (CAGR), from $606.8M to $707.22M.
What does business segments — total costs & expenses mean?
This metric represents the aggregate operating and non-operating costs incurred by the reportable segment to support its business activities. It encompasses cost of goods sold, research and development, and selling, general, and administrative expenses. Monitoring this figure helps assess the operational efficiency and cost structure of the segment.

Ask your AI about Pacira BioSciences, Inc.'s business segments — total costs & expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude